氯倍他索丙酸酯眼用混悬液治疗无并发症白内障术后炎症与疼痛
CPN达到主要终点,术后第15天前房细胞计数为0和眼痛分级为0的比例均显著高于安慰剂(P<0.001),且耐受性良好,安全性与安慰剂相似。
要点
- CPN 0.05%每日两次用14天可快速持续清除白内障术后炎症和眼痛。
- 术后第15天CPN组58.2%前房细胞计数为0,安慰剂组17.3%(P<0.001)。
- CPN组88.5%眼痛分级为0,安慰剂组45.8%(P<0.001),且视力改善更快。
核心结论
- CPN 0.05%每日两次用14天安全且快速改善无并发症白内障术后炎症、眼痛和视力。
研究设计与样本
- 两项多中心随机双盲安慰剂对照3期试验,设计相同,第二项试验含角膜内皮细胞安全性亚研究。
主要发现
- 术后第15天CPN组58.2%、安慰剂组17.3%前房细胞计数为0(P<0.001)。
- 术后第15天CPN组88.5%、安慰剂组45.8%眼痛分级为0(P<0.001)。
- 术后第4天CPN组视力改善快于安慰剂组(P<0.001)。
- 停药1周后术后第22天疗效参数无反弹,安慰剂组更多患者需要补救药物(P<0.001)。
- CPN 0.05%耐受良好,安全性与安慰剂相似,无有意义眼压升高或角膜内皮细胞改变。
关键数值与推荐
- 主要疗效终点:术后第8天前房细胞计数为0并维持至第15天的参与者百分比。
- 主要疗效终点:术后第4天眼痛分级为0并维持至第15天的参与者百分比。
- CPN 0.05%或安慰剂每日两次滴术眼,持续14天。
临床怎么用
- 无并发症白内障术后可考虑CPN 0.05%每日两次用14天以控制炎症和眼痛。
- 用药期间无需特殊担心眼压升高或角膜内皮细胞改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of clobetasol propionate ophthalmic suspension (CPN) 0.05% to treat ocular inflammation and pain after cataract surgery. DESIGN: Two multicenter, randomized, double-masked, placebo-controlled phase 3 trials, identical in design except for a corneal endothelial cell (EC) safety substudy in the second trial. PARTICIPANTS: Patients who underwent uncomplicated cataract surgery. METHODS: After surgery, participants were randomized 1:1 to CPN 0.05% or placebo 1 drop twice daily for 14 days instilled into the operated eye. MAIN OUTCOME MEASURES: Efficacy outcomes were: (1) the percentage of participants with anterior chamber cell (ACC) count of 0 at postoperative day (POD) 8, maintained through POD 15; (2) the percentage of participants with ocular pain (OP) grade of 0 at POD 4, maintained through POD 15; and (3) inflammation, OP grade, and visual acuity at PODs 4, 8, 15, and 22. Safety outcomes were adverse event reports, ophthalmoscopy, intraocular pressure (IOP), and EC assessments. RESULTS: Seven hundred forty-eight participants were randomized to receive CPN 0.05% (n = 366) or placebo (n = 382). The demographic and baseline characteristics were well balanced between the 2 groups. CPN 0.05% met the primary end points, producing rapid and sustained clearance of inflammation and absence of OP that was statistically significantly greater than placebo. At POD 15, 58.2% of participants receiving CPN 0.05% and 17.3% of participants receiving placebo had an ACC count of 0 (P < 0.001), and 88.5% of participants receiving CPN 0.05% and 45.8% of participants receiving placebo had an OP grade of 0 (P < 0.001). By POD 4, visual acuity had improved more rapidly in the CPN 0.05% group than in the placebo group (P < 0.001). No rebound of the efficacy parameters was noted on POD 22 after CPN 0.05% was stopped for 1 week. More participants receiving placebo than receiving CPN 0.05% required rescue medications (P < 0.001). CPN 0.05% was well tolerated, with a safety profile similar to that of the placebo. No meaningful IOP increases or corneal EC changes occurred in the group receiving CPN 0.05%. CONCLUSIONS: CPN 0.05% twice daily for 14 days was safe and rapidly improved inflammation, OP, and visual acuity after cataract surgery. FINANCIAL DISCLOSURES: Disclosures are in the Footnotes and Disclosures.
引用
- Korenfeld MS, Levenson J, Sadri E, et al. Clobetasol Propionate Ophthalmic Suspension to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery. Ophthalmology. 2026. PMID: 42097332. doi:10.1016/j.ophtha.2026.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。